Replies to post #22804 on Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

Conflicting data as the recent PR from Cellceutix dtd 1-24-13, see their website, states "Cellceutix was advised by the researchers that "the Kevetrin/sunitinib combination is the first we've used in which actual tumor shrinkage is noted." This was referencing the in vivo research at BIDMC which is the acknowledged leader in renal cancer research.

I don't see how sunitinib could have been successful prior to this in shrinking renal tumors for the researchers to have made this statement which Cellceutix had in quotes so it is exactly what they said, not an interpretation or summary of what they stated. Our belief (those on this board, hope most feel this way) is that it is Kevetrin that in combination with suni... that is causing the shrinkage as suni... couldn't do it alone.

I didn't read your article so I don't know what info sunit... put out as to it's effect alone on renal tumors.

Seems to be a good question to ask Leo E. if indeed the reports are at odds.

[BonelessCat]

There are Renal Cell Carcinomas that are highly drug resistant including Sunitinib. Pfizer hopes that Kevetrin will increase Sunitinib efficacy against all renal carcinomas and eliminate even the most drug resistant.

Second, the studies include at least two treatment groups in a comparative protocol where outcomes for all groups, Kevitrin and Kevetrin/Sunitinib, are directly contrasted. The proof of theory goal is that Kevetrin allows for greater tumor growth arrest and shrinkage than Sunitinib alone.

[Whoops]

I would assume Sunitinib alone would have been compared sunitinib+Kevetrin and a control. I am sure BIDC will publish a peer-reviewed article, perhaps at ASCO!, on the experiment especially because they are applying for a grant.

If you search the web there is a lot of theoretical research done trying to tackle drug-resistant 786 in RCC so we know its not easy. But we will get a "free" phase 2 human trial in combo.

We will all have to excitedly wait for the paper because they probably won't leak much until its published. We know that BIDMC is a leader in this fight so I will remain impressed by their comments.





In response to:
"How are the researchers and/or company attributing that Kevetrin has made a difference and that the observed shrinkage is not due to Sunitinib ? Is there a article to show that sunitinib is not effective in cell line 786 ?"